Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to boost lymphoma treatment

NCT ID NCT07712588

Not yet recruiting Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial tests whether adding an experimental drug called birelentinib to standard chemotherapy (R-CHOP) improves outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Participants receive either birelentinib plus R-CHOP or a placebo plus R-CHOP. The study measures safety and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called birelentinib combined with standard chemotherapy (R-CHOP)
What this could lead to
If successful, this could lead to a more effective first-line treatment for diffuse large B-cell lymphoma, potentially improving survival and remission rates.
What could go wrong
This is an early-to-mid-stage trial, so the drug may not prove more effective than standard therapy and could have unforeseen side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital of Shandong Frist Medical University

    Jinan, Shangdong, China

    Contact

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

    Contact

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

    Contact

  • Hunan Cancer Hospital

    Changsha, Hunan, China

    Contact

  • Shanghai Jiao Tong University School of Medicine, Ruijin Hospital

    Shanghai, Shanghai Municipality, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.